In situ-activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
Authors:
- Xin-Ge WangXWXin-Ge Wang
- Yue-Lan HuangYHYue-Lan Huang
- Xuan-Ren ShiXSXuan-Ren Shi
- Zhen-Ping ZouZZZhen-Ping Zou
- Ying ZhouYZYing Zhou
- Bang-Ce YeBYBang-Ce Ye
Open Access
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
This publication has 38 references indexed in Scilit:
- Self‐Adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics DeliveryAdvanced Science, 2025
- Engineered bacteria potentiate cancer immunotherapyChinese Chemical Letters, 2025
- Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers GM-CSFActa Pharmaceutica Sinica B, 2024
- Dendritic cells as shepherds of T cell immunity in cancerImmunity, 2023
- Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancerInternational Immunopharmacology, 2023
- Characterizing and utilizing oxygen-dependent promoters for efficient dynamic metabolic engineeringMetabolic Engineering, 2023
- Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in miceCell Host & Microbe, 2022
- Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimuriumMolecular Therapy, 2022
- Role of GM-CSF in regulating metabolism and mitochondrial functions critical to macrophage proliferationMitochondrion, 2021
- Expressivity tag: A novel tool for increased expression in Escherichia coliJournal of Biotechnology, 2011